Further ROC curve analysis demonstrated that irisin could effectively discriminate breast cancer patients with 62.7% sensitivity and 91.1% specificity at a cut-off point of 3.21 μg/mL, suggesting that serum irisin may serve as a potential biomarker for the early detection of breast cancer (Provatopoulou et al., 2015). This evidence concerns the gene FNDC5 and breast carcinoma.